Sacubitril/Valsartan Tested in Heart Failure Patients With Prosthetic Heart Valves
Tests sacubitril/valsartan in adults with prosthetic heart valves and reduced-pumping heart failure.
Plain-language title generated from the registry record
Registry title: Sacubitril/Valsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction
Key facts
- Where
- Kafr ash Shaykh, EgyptSee the site
Where in Egypt
- Kafrelsheikh UniversityKafr ash Shaykh, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Kafrelsheikh University
- Trial code
- NCT07192341
- Record updated
- 30 September 2025
- Original description
This study aims to evaluate the effect of sacubitril/valsartan in patients with prosthetic heart valves with heart failure with reduced ejection fraction (HFrEF).Read full original descriptionShow less
Effect of Sacubitril/Valsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction
This study aims to evaluate the effect of sacubitril/valsartan in patients with prosthetic heart valves with heart failure with reduced ejection fraction (HFrEF).
Inclusion: Age ≥ 18 years old; Both sexes; Patients with a history of prosthetic heart valves; Patients diagnosed with heart failure with reduced ejection fraction (HFrEF), defined as left ventricular ejection fraction (LVEF) ≤ 40% with New York Heart Association (NYHA) functional class II-IV.
Exclusion: Serious adverse drug reactions or serious complications over the course of treatment; Severe pulmonary hypertension; Malignant arrhythmia; Malignant tumor; Known history of hereditary or primary angioedema; Severe hepatic [alanine aminotransferase (ALT) >120 U/L] and renal insufficiency [estimated glomerular filtration rate (eGFR) <30 mL/min]; Serum potassium >5.3 mmol/L; Hemodynamic instability; Use of a circulatory auxiliary circulation device; Blood pressure <100/60 mmHg.